<DOC>
	<DOCNO>NCT00808080</DOCNO>
	<brief_summary>The aim protocol investigate novel form immune therapy patient acute myelogenous leukemia ( AML ) remission ( CR ) high risk relapse .</brief_summary>
	<brief_title>A Clinical Trial Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell ( AHSC ) Transplantation Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>Primary Aim : To conduct Phase 1/2 clinical trial autologous CTL-mediated immunotherapy homogeneous group patient AML recently receive autologous hematopoietic stem cell transplant . Specifically : Phase 1 : To determine MTD autologous AML-reactive culture CTL patient AML recently receive AHSCT . Phase 2 : To determine 1 year progression-free survival study group vs institutional historical control group compose sequential series recent patient receive AHSCT AML .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Inclusion Criteria ( Initial Eligibility Screen ) : Diagnosis AML , M3 At least 10 % circulate leukocyte AML blast cell Age 18 75 Sex male female Patient consider potential candidate AHSCT Exclusion criterion ( Initial Eligibility Screen ) : Participation another immunotherapy trial within 30 day Presence active malignancy AML History autoimmune disease require systemic treatment ECOG performance status 3 4 Major organ system dysfunction Recent ( 30 day ) current use steroid topical skin preparation History allogeneic transplant Patients , reason deem candidate AHSCT Eligibility autologous CTL Infusion : Patient CTL sufficient number suitable infusion Patient stable , afebrile , engraft , ECOG status 02 , CR receive AHSCT 45 60 day earlier . Exclusion delay criterion : Temperature &gt; 38 C and/or know infected Absence engraftment ANC &gt; 500 Plt &gt; 20,000 unsupported Life expectancy le 6 week Autoimmune disease require systemic treatment . ECOG performance status 3 4 Major organ system dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>AML</keyword>
</DOC>